Latest Breaking News On - Paris descartes - Page 6 : comparemela.com

Published: Feb 03, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate” or the “ Company”) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET. The event will feature presentations from the Company’s executive leadership team, as well as the following KOLs: Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator of Innate’s Phase 2 TELLOMAK clinical trial, which is evaluating lacutamab in mycosis fungoides and Sézary syndrome; and

Universitaire necker enfants maladesPierluigi porcuBristol myers squibbNovo nordiskOlivier hermineDivision of hematologic malignanciesUniversity of paris descartesDivision of adult hematologyExchange commissionFrench financial markets authorityCompany annual report on formMember of the lymphoma study associationEuronext parisMedical oncologyCutaneous biologyHematologic malignancies